Amundi increased its stake by 32.0%, filed disclosure regarding Q2 purchases, and Citigroup initiated coverage with a 'buy' rating.
1 report, 1 independent
Updated Sep 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amundi increased its stake by 32.0%, filed disclosure regarding Q2 purchases, and Citigroup initiated coverage with a 'buy' rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amundi
French subsidiary jointly created by Crédit Agricole and Société Générale
-
Citigroup
American investment bank and financial services corporation
-
Securities and Exchange Commission
government agency of the Philippines
- FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
- Multiple major financial firms, including Jane Street, Grayscale Investments, Andreessen Horowitz, and Charles Schwab, submitted comments to the SEC regarding the review of ETFs.
Related events
- Amundi purchased a new stake in Newmont Corporation stock on October 16, 2026.
- Amundi increased its holdings in Applied Materials stock, filing the transaction with the SEC.
- Amundi raised its holdings in Microsoft shares on October 16, 2026.
- Amundi and Bank of America increased their positions in Microsoft shares, with filings tracked by the SEC.
- Amundi increased its stock holdings in Apple Inc. on October 20, 2026.